
|Articles|July 1, 2004
PDT laser receives expedited review status
The FDA has accepted for filing and granted expedited review status to the Miravant Medical Technologies' premarket application for the IRIS Medical OcuLight 664 ophthalmic photodynamic therapy (PDT) laser used to activate drug SnET2, a proposed drug and light treatment for patients with wet age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
2
AAO 2025: The outcomes of the VERONA and DAVIO-2 studies set up continued phase 3 research
3
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
4
AAO 2025: Arshad M. Khanani, MD, highlights 3-year results from the GATHER2 open-label extension trial
5